MaxCyte has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. “Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the world. He knows firsthand what it takes to translate strategy into growth. I am confident that Sidharth’s expertise will support MaxCyte’s next chapter of growth,” said Maher Masoud, President and Chief Executive Officer.
About Sidharth Kapileshwar
Kapileshwar joins MaxCyte from Danaher Corporation, where he served as Vice President of Innovation for the Life Sciences Platform. “MaxCyte has been an early pioneer in applying flow electroporation at clinical and commercial scale for cell and gene therapies, and its technologies are foundational to where the field is headed. That’s exactly the kind of opportunity I want to help build at MaxCyte,” Kapileshwar said. “I’ve spent my career helping large, global organizations sharpen their strategies and execute their next phase of growth, and I’m excited to bring that same momentum to MaxCyte.”
Over nearly 25 years, Kapileshwar held corporate development, strategy, innovation, and M&A leadership roles at GE Healthcare, Beckman Coulter, and Halma plc.
Kapileshwar holds a Master of Science in Engineering from The Ohio State University, an MBA from the University of Chicago Booth School of Business, and a Bachelor of Technology in Engineering from the Indian Institute of Technology Bombay.
About MaxCyte
MaxCyte is a leading cell-engineering company driving the discovery, development, and commercialization of next-generation cell therapies. Its Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient, and scalable cell engineering, supported by expert scientific, technical, and regulatory guidance that empowers researchers around the world to engineer diverse cell types and payloads. The company has spent more than 25 years advancing cell engineering and shaping the future of medicine.
